Karius, a leader in infectious disease diagnostics, recently secured $100 million in Series C funding. This marks a significant milestone for the company.
The funding is co-led by Khosla Ventures, joined by 5AM Ventures and Gilde Healthcare. It signifies a robust vote of confidence in Karius’ innovative approach to diagnostics.
Karius, fortified by substantial investment and promising trial results, is well-equipped to revolutionise infectious disease diagnostics.
Their commitment to innovation and precision positions them as a formidable force in the fight against global health challenges.
Karius, fortified by substantial investment, is poised to revolutionise infectious disease diagnostics. Their commitment to innovation and precision positions them as a formidable force in tackling global health challenges.
